NCT06835465View on ClinicalTrials.gov

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

May 6, 2025

Study Completion Date

May 6, 2025

Conditions
Healthy Participants
Interventions
DRUG

Divarasib

Divarasib will be administered as a single oral dose as specified for the respective period.

DRUG

Rifampin

Rifampin will be administered QD on Days 1 to 7 and Days 9 to 13 and as a single oral dose on Day 8 as specified for the respective period.

Trial Locations (1)

75247

Fortrea Dallas CRU, Dallas

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY